{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glaucoma+and+Ocular+Hypertension&page=9",
    "query": {
      "condition": "Glaucoma and Ocular Hypertension",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 408,
    "total_pages": 41,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glaucoma+and+Ocular+Hypertension&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glaucoma+and+Ocular+Hypertension&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T21:14:02.301Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02444767",
      "title": "Bimatoprost Ocular Insert Pharmacokinetic Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "13mg Bimatoprost Ocular Insert",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ForSight Vision5, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 11,
      "start_date": "2015-03",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2015-05-14",
      "last_synced_at": "2026-10-13T21:14:02.301Z",
      "location_count": 1,
      "location_summary": "Artesia, California",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02444767"
    },
    {
      "nct_id": "NCT01110499",
      "title": "Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Primary Open-Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "AGN-210961 Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 2",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 3",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 4",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 5",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 6",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 7",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost ophthalmic solution 0.03%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2010-06",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2014-08-05",
      "last_synced_at": "2026-10-13T21:14:02.301Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110499"
    },
    {
      "nct_id": "NCT01540370",
      "title": "Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "No Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2012-02",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2013-09-19",
      "last_synced_at": "2026-10-13T21:14:02.301Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01540370"
    },
    {
      "nct_id": "NCT05913232",
      "title": "Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma Open-Angle Primary",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "H-1337 0.6%",
          "type": "DRUG"
        },
        {
          "name": "H-1337 1.0%",
          "type": "DRUG"
        },
        {
          "name": "H-1337 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Timolol 0.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "D. Western Therapeutics Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 201,
      "start_date": "2023-08-28",
      "completion_date": "2024-08-29",
      "has_results": true,
      "last_update_posted_date": "2025-08-27",
      "last_synced_at": "2026-10-13T21:14:02.301Z",
      "location_count": 9,
      "location_summary": "Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Albany",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05913232"
    },
    {
      "nct_id": "NCT01749904",
      "title": "Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open-Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "BOL-303259-X",
          "type": "DRUG"
        },
        {
          "name": "Timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2013-01-31",
      "completion_date": "2015-09-30",
      "has_results": true,
      "last_update_posted_date": "2018-11-07",
      "last_synced_at": "2026-10-13T21:14:02.301Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01749904"
    },
    {
      "nct_id": "NCT00478036",
      "title": "Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Acular LS",
          "type": "DRUG"
        },
        {
          "name": "Pred Forte",
          "type": "DRUG"
        },
        {
          "name": "Refresh Tears",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2007-05",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2016-10-07",
      "last_synced_at": "2026-10-13T21:14:02.301Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00478036"
    },
    {
      "nct_id": "NCT01927406",
      "title": "The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thyroid Eye Disease",
        "Ocular Hypertension",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Prostaglandin Analog",
          "type": "DRUG"
        },
        {
          "name": "Timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-06",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2018-05-15",
      "last_synced_at": "2026-10-13T21:14:02.301Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01927406"
    },
    {
      "nct_id": "NCT04735653",
      "title": "The Support, Educate, Empower (SEE) Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Personalized Glaucoma Coaching",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Enhanced Standard care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 236,
      "start_date": "2021-04-27",
      "completion_date": "2024-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-10-13T21:14:02.301Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Detroit, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04735653"
    },
    {
      "nct_id": "NCT00159653",
      "title": "A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Xalacom",
          "type": "DRUG"
        },
        {
          "name": "Xalatan",
          "type": "DRUG"
        },
        {
          "name": "Timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2005-07",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-10-13T21:14:02.301Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Poway, California • Redding, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00159653"
    },
    {
      "nct_id": "NCT03868254",
      "title": "Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "XEN Group",
          "type": "DEVICE"
        },
        {
          "name": "Phacoemulsification",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 174,
      "start_date": "2019-04-05",
      "completion_date": "2019-10-25",
      "has_results": true,
      "last_update_posted_date": "2020-11-17",
      "last_synced_at": "2026-10-13T21:14:02.301Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03868254"
    }
  ]
}